Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2025-08-26 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
突发事件危机处理应急制度（2025年8月）
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '突发事件危机处理应急制度' (Emergency Crisis Management System) issued by the company's board. It outlines procedures for handling sudden crisis events, including organizational structure, classification of incidents, prevention, emergency response, and responsibilities. There is no financial data, no mention of financial results, no shareholder meeting materials, no voting results, no audit or legal proceedings updates, no capital or financing updates, and no earnings or annual report content. The document is a governance-related internal control policy rather than a report or announcement. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-26 Chinese
风险投资管理制度（2025年8月）
Governance Information Classification · 95% confidence The document is titled '风险投资管理制度' which translates to 'Risk Investment Management System' and contains detailed internal rules and procedures regarding the company's risk investment activities, decision-making authority, responsibilities, information disclosure, and compliance with regulatory requirements. It is a governance-related document outlining internal controls and management policies rather than a financial report, announcement, or regulatory filing. The document is not an annual or interim report, earnings release, or any form of shareholder meeting material. It is a governance information document describing the company's internal rules and governance practices related to risk investment management. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3887 characters, which is sufficient for a substantive governance policy document, not a brief announcement or certification.
2025-08-26 Chinese
对外担保管理制度（2025年8月）
Governance Information Classification · 95% confidence The document is titled '哈尔滨誉衡药业股份有限公司 对外担保管理制度' which translates to 'Harbin Yuheng Pharmaceutical Co., Ltd. External Guarantee Management System'. It is a detailed internal policy document outlining the rules, procedures, responsibilities, and risk management related to the company's external guarantees. The content includes references to company law, securities law, board approval processes, risk controls, and internal audit functions. There is no indication that this is a financial report, earnings release, or regulatory filing announcing results or changes. It is not a report publication announcement or certification. The document is a governance-related internal control policy, detailing the company's governance practices around external guarantees. Therefore, the most appropriate classification is Governance Information (CGR). The document length (6332 characters) and detailed procedural content support this classification with high confidence.
2025-08-26 Chinese
2025年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2025 年半年度财务报告" which translates to "2025 Semi-Annual Financial Report." It contains detailed financial statements including consolidated balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2025. The report explicitly states it is unaudited and includes comprehensive financial data and analysis for the half-year period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is about 15,000 characters long, indicating it is the full report, not just an announcement or certification. Therefore, the correct classification is IR. H1 2025
2025-08-26 Chinese
年报信息披露重大差错责任追究制度（2025年8月）
Governance Information Classification · 95% confidence The document is a detailed internal policy document from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the accountability system for major errors in annual report information disclosure. It outlines principles, definitions, procedures for identifying and correcting major accounting errors in annual financial reports, and the responsibility and disciplinary measures for such errors. The document references annual reports and financial reporting standards but does not itself contain financial statements or actual financial data. It is not an annual report (10-K), audit report (AR), or interim report (IR). It is also not an announcement or publication notice of a report (RPA), nor a certification or attestation (RNS). Instead, it is a governance-related document detailing internal rules and procedures related to annual report disclosures and accountability. Therefore, the most appropriate classification is Governance Information (CGR). The document length (5121 characters) and content support this classification with high confidence.
2025-08-26 Chinese
董事会薪酬与考核委员会议事规则（2025年8月）
Governance Information Classification · 100% confidence The document is titled as the "Board of Directors Remuneration and Assessment Committee Rules" of Harbin Yuheng Pharmaceutical Co., Ltd. It details the establishment, composition, responsibilities, decision-making procedures, meeting rules, and record-keeping of the Board's Remuneration and Assessment Committee. The content focuses on governance practices related to board and senior management remuneration and assessment policies, committee structure, and procedural rules. There is no financial data, earnings information, or report publication announcement. The document is a governance-related internal rules document, fitting the Governance Information (CGR) category.
2025-08-26 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.